Twenty relapsing-remitting (RR) clinically definite MS patients were treated with 9 MIU intramuscular recombinant interferon alpha-2a (rIFNA) (Rof eron-A, Roche) (n=12) or placebo (n=8) every other day for 6 months and followed up for a further 6 months after stopping treatment Numbers of active lesions at MRI and of patients with clinical-MRI signs of disease activity and lymphocyte interferon gamma production, which were decreased during treatment, returned to values similar to baseline and placebos after stopping treatment rIFNA chronic therapy seems therefore needed in order to maintain drug efficacy. Side effect prof ile was monitored, too, for over 1 year in the same 20 patients plus 25 additional RR MS patients. Besides the typical side effects of type 1 interferon therapy (fever, fatigue, depression, lymphopenia, hepatic enzyme elevation), occurrence of serum autoAbs was noted in 30% patients (in 60% antinuclear and in 80% antithyroid autoAbs). In two patients rIFNA treatment was stopped, in one case for antithyroid autoAbs and hypothyroidism, in the other for antinuclear autoAbs and a five-fold increase of ALT. A careful monitoring of serum autoAbs and of signs of thyroid or liver damage must always precede and accompany longterm type 1 IFN therapy.
1 Olsson T. (1994) Role of cytokines in multiple sclerosis and experimental autoimmune encephalomyelitis. Eur J Neurol1: 7–19.
2.
2 Pober JS et al. (1983) Ia expression by vascular endothelium is inducible by activated T cells and by human gamma-interferon. J Exp Med157: 1339–1353.
3.
3 Fierz W et al. (1985) Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol134: 3785–3793.
4.
4 Panitch HS, Hirsch RL, Schindler J, Johnson KP. (1987) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology37: 1097–1102.
5.
5 Woodroof e MN, Cuzner ML. (1993) Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine5: 583–588.
6.
6 Link J et al. (1994) Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurol36: 379–386.
7.
7 Rieckmann P et al. (1994) Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology44: 1523–1526.
8.
8 Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudik RA. (1995) The interferons: Biological effect, mechanism of action and use in Multiple Sclerosis. Ann Neurol1: 7–15.
9.
9 The IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a muticenter, randomized, double-blind, placebo-controlled trial.Neurology43: 655–661.
10.
10 Paty DW, Li DKB, the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43: 662–667.
11.
11 Durelli L et al. (1994) Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology44: 406–413.
12.
12 Quesada JR. (1992) Toxicity and side effects of interferons. In: Baron S, Coppenhaver DH, Dianzani F, Fleischmann Jr. WR, Hughes Jr. TK, Klimpel GR, Niesel DW, Stanton GJ, Tyring SK, (eds.) Interferon: principles and medical applications.Galveston: The University of Texas Medical Branch Department of Microbiology. 427–432.
13.
13 Conlon KC et al. (1990) Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer65: 2237–2242.
14.
14 Papo T et al. (1992) Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Int Med116: 51–53.
15.
15 Waguri M et al. (1994) Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract23: 33–36.
16.
16 Huber M, Bamborschke S, Assheuer J, Heiss WD. (1988) Intravenous natural interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings. J Neurol235: 171–173.
17.
17 Kinnunen E et al. (1993) Effects of recombinant alpha-2b interferon therapy in patients with progressive MS. Acta Neurol Scand87: 457–460.
18.
18 Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol13: 227–231.
19.
19 Sipe JC et al. (1984) A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology34: 1368–1372.
20.
20 Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology33: 1444–1452.
21.
21 Borden E et al. (1986) Biological response modification in man: measurement of interferon-induced proteins. In: Baron S, Dianzani F, Stanton GJ, Fleischmann WR Jr. (eds.) The interferon system: a current review.Austin, TX: University of Texas Press, 1–7.
22.
22 Plantanias LC, Golomb HM. (1992) Clinical use of interferons: hairy cell, chronic myelogenous and other leukemias. In: Baron S, Coppenhaver DH, Dianzani F, Fleischmann Jr. WR, Hughes Jr. TK, Klimpel GR, Neisel DW, Stanton GJ, Tyring SK (eds) Interferon: principles and medical applications.The University of Texas Medical Branch Department of Microbiology, Galveston, 487–499.
23.
23 Saracco G et al. (1993) Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon alpha-2b. Hepatology18: 1300–1305.
24.
24 Willoughby EW et al. (1989) Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol25: 43–49.
25.
25 Harris JO et al. (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol29: 548–555.
26.
26 Hooffnagle JH (1992) Interferon therapy of viral hepatitis. In: Baron S, Coppenhaver DH, Dianzani F, Fleischmann Jr. WR, Hughes Jr. TK, Klimpel GR, Niesel DW, Stanton GJ, Tyring SK, (eds) Interferon: principles and medical applications.The University of Texas Medical Branch Department of Microbiology, Galveston, 433–462.
27.
27 Johnson HM, Bazer FW, Szente BE, Jarpe RA. (1994) How interferons fight disease. Sci Amer5: 40–47.
28.
28 Jacobs L et al. and The Multiple Sclerosis Collaborative Research Group. (1994) Results of a phase III trial of intramuscular recombinant beta interferon treatment for multiple sclerosis (abstract). Ann Neurol36: 259.
29.
29 Jacobs L, Munschaner F. (1992) Treatment of multiple sclerosis with interferons. In: Rudick R, Goodkin D, (eds.) Treatment of multiple sclerosis.Springer-Verlag. 233–250.
30.
30 Gauci L. (1987) Management of cancer patients receiving interferon alfa-2aInt J Cancer (suppl 1): 21–30.
31.
31 Knobler RL et al. (1993) Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res13: 333–340.
32.
32 Neilley LK et al. (1995) Side-effect prof ile of interferon beta-1b (Betaseron) (abstract). Neurology45: (suppl 4): A437.
33.
33 Arnason BGW, Jensen M, Lledo A, Dayal A. (1995) Interferon beta: induction in multiple sclerosis (MS) increases interferon gamma-secreting cells (abstract). Neurology45 (suppl 4): A437.
